ID   SK-BR-3/PacR
AC   CVCL_B7P8
DR   cancercelllines; CVCL_B7P8
DR   Wikidata; Q112930399
RX   PubMed=27664577;
RX   PubMed=29625142;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol).
CC   Sequence variation: Gene deletion; HGNC; 1748; CDH1; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line).
CC   Miscellaneous: Cell line no longer available (personal communication of Daniel P.).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C5214; Breast adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0033 ! SK-BR-3
SX   Female
AG   43Y
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 05-10-23; Version: 5
//
RX   PubMed=27664577; DOI=10.1016/j.taap.2016.09.020;
RA   Nemcova-Furstova V., Kopperova D., Balusikova K., Ehrlichova M.,
RA   Brynychova V., Vaclavikova R., Daniel P., Soucek P., Kovar J.;
RT   "Characterization of acquired paclitaxel resistance of breast cancer
RT   cells and involvement of ABC transporters.";
RL   Toxicol. Appl. Pharmacol. 310:215-228(2016).
//
RX   PubMed=29625142; DOI=10.1016/j.taap.2018.04.002;
RA   Jelinek M., Balusikova K., Daniel P., Nemcova-Furstova V.,
RA   Kirubakaran P., Jacek M., Wei L.-F., Wang X., Vondrasek J., Ojima I.,
RA   Kovar J.;
RT   "Substituents at the C3' and C3'N positions are critical for taxanes
RT   to overcome acquired resistance of cancer cells to paclitaxel.";
RL   Toxicol. Appl. Pharmacol. 347:79-91(2018).
//